Nationwide Children's News Releases
Viewing: 31-40 of 96 | All
Jan 10, 2017
Sarepta Therapeutics Enters Into License Agreement with Nationwide Childrens Hospital for Galgt2 Gene Therapy Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a license agreement with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Paul Martin, PhD.
Jan 10, 2017
Sarepta Therapeutics Enters Into Research Agreement and Option Agreement with Nationwide Childrens Hospital for Microdystrophin Gene Therapy Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research agreement with Nationwide Children’s Hospital on their microdystrophin gene therapy program.
Jan 03, 2017
Flanigan Named to Neuromuscular, Gene Therapy Leadership Roles
Beginning January 1, 2017, Kevin Flanigan, MD, will become the director of the Center for Gene Therapy and the Neuromuscular Disorders program at Nationwide Children’s Hospital. Dr.
Oct 12, 2016
Nationwide Childrens Hospital Neuromuscular Disease Researchers Receive $7.5 Million NIH Grant
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announced four new Centers of Research Translation awards today.
Oct 04, 2016
Perky Jerky® to Support Nationwide Childrens Hospital Beginning in October
Nationwide Children’s Hospital and Perky Jerky® announced today that from October through December, customers at 16 participating Kroger stores will have an opportunity to donate to Nationwide Children’s by purchasing Perky Jerky®.
Sep 26, 2016
Oligodendrocytes Induce Motor Neuron Death in ALS
A first-of-its-kind oligodendrocyte in vitro model shows that human cells normally supportive of motor neuron function play an active role in amyotrophic lateral sclerosis pathogenesis – and this discovery may point the way toward therapeutic timing and targets.
Sep 20, 2016
Nationwide Childrens Hospital Leads Effort for Gene Therapy Treatment for Duchenne Muscular Dystrophy
Sarepta Therapeutics announced yesterday that the FDA has granted accelerated approval for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Nationwide Children's Hospital was the sole original site for the clinical study that resulted in this approval, led by Dr.
Jul 20, 2016
AveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the U.S.
Jul 01, 2016
Dean Lee, MD, PhD, to Lead Cell Therapy Programs at Nationwide Childrens Hospital and The Ohio State University Comprehensive Cancer Center
Dean Lee, MD, PhD, has been named the director of the Cellular Therapy and Cancer Immunotherapy Program for Nationwide Children’s Hospital’s Division of Hematology/Oncology/BMT and Center for Childhood Cancer and Blood Diseases. Dr.
Feb 29, 2016
Loss of MHCI in Motor Neurons Leads to ALS Astrocyte Toxicity
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a devastating progressive neurodegenerative disease that results in the death of motor neurons, the nerve cells that control muscles.